These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22421757)

  • 1. [Borderline resectable pancreatic cancer - a definition and effective treatment strategy].
    Yokoyama Y; Ebata T; Igami T; Sugawara G; Takahashi Y; Kokuryo T; Tsunoda N; Fukaya M; Uehara K; Itatsu K; Yoshioka Y; Nagino M
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):337-41. PubMed ID: 22421757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: a review of current results.
    Chua TC; Saxena A
    Surg Oncol; 2011 Dec; 20(4):e161-8. PubMed ID: 21704510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to define and manage borderline resectable pancreatic cancer.
    Papavasiliou P; Chun YS; Hoffman JP
    Surg Clin North Am; 2013 Jun; 93(3):663-74. PubMed ID: 23632151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer.
    Goff SL; Chabot JA
    Cancer J; 2012; 18(6):602-8. PubMed ID: 23187848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
    Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.
    He J; Lv N; Yang Z; Luo Y; Zhong W; Wu C
    Int J Surg; 2024 Jun; 110(6):3900-3909. PubMed ID: 38935819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
    Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
    Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We?
    Wolff RA
    Surg Clin North Am; 2018 Feb; 98(1):95-111. PubMed ID: 29191281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant treatments for resectable pancreatic cancer.
    Ueno H; Kosuge T
    J Hepatobiliary Pancreat Surg; 2008; 15(5):468-72. PubMed ID: 18836798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
    di Sebastiano P; Grottola T; di Mola FF
    Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
    Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
    Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
    Kang CM; Hwang HK; Choi SH; Lee WJ
    Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma.
    Stojadinovic A; Brooks A; Hoos A; Jaques DP; Conlon KC; Brennan MF
    J Am Coll Surg; 2003 Jun; 196(6):954-64. PubMed ID: 12788434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment.
    Mornex F; Girard N; Delpero JR; Partensky C
    Semin Radiat Oncol; 2005 Oct; 15(4):226-34. PubMed ID: 16183476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant therapy in resectable pancreatic cancer: a critical review.
    Belli C; Cereda S; Anand S; Reni M
    Cancer Treat Rev; 2013 Aug; 39(5):518-24. PubMed ID: 23122322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments in the management of borderline resectable pancreatic cancer.
    Sharma J; Ng J; Goodman MD; Saif MW
    JOP; 2013 Mar; 14(2):123-5. PubMed ID: 23474551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
    Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
    J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a role for chemoradiotherapy in the treatment of pancreatic carcinoma?
    Pasetto LM; Jirillo A; Stefani M; Monfardini S
    Anticancer Res; 2003; 23(3C):2805-13. PubMed ID: 12926117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.